Abstract:Importance: Advancing precision psychiatry, where treatments are based on an individual's biology rather than solely their clinical presentation, requires attention to several key attributes for any candidate biomarker. These include test-retest reliability, sensitivity to relevant neurophysiology, cost-effectiveness, and scalability. Unfortunately, these issues have not been systematically addressed by biomarker development efforts that use common neuroimaging tools like magnetic resonance imaging (MRI) and electroencephalography (EEG). Here, the critical barriers that neuroimaging methods will need to overcome to achieve clinical relevance in the near to intermediate term are examined. Observations: Reliability is often overlooked, which together with sensitivity to key aspects of neurophysiology and replicated predictive utility, favors EEG-based methods. The principal barrier for EEG has been the lack of large-scale data collection among multisite psychiatric consortia. By contrast, despite its high reliability, structural MRI has not demonstrated clinical utility in psychiatry, which may be due to its limited sensitivity to psychiatry-relevant neurophysiology. Given the prevalence of structural MRIs, establishment of a compelling clinical use case remains its principal barrier. By contrast, low reliability and difficulty in standardizing collection are the principal barriers for functional MRI, along with the need for demonstration that its superior spatial resolution over EEG and ability to directly image subcortical regions in fact provide unique clinical value. Often missing, moreover, is consideration of how these various scientific issues can be balanced against practical economic realities of psychiatric health care delivery today, for which embedding economic modeling into biomarker development efforts may help direct research efforts. Conclusions and relevance: EEG seems most ripe for near- to intermediate-term clinical impact, especially considering its scalability and cost-effectiveness. Recent efforts to broaden its collection, as well as development of low-cost turnkey systems, suggest a promising pathway by which neuroimaging can impact clinical care. Continued MRI research focused on its key barriers may hold promise for longer-horizon utility.

Modern Methods for Unraveling Cell- and Circuit-Level Mechanisms of Neurophysiological Biomarkers in Psychiatry

Physiologically informed neuromodulation

Changing Brain Networks Through Non-invasive Neuromodulation

Wiring the depressed brain: optogenetic and chemogenetic circuit interrogation in animal models of depression

What can neuroimaging of neuromodulation reveal about the basis of circuit therapies for psychiatry?

Molecular Imaging in Neuroscience Research with Small-Animal PET in Rodents

Bringing Imaging Biomarkers Into Clinical Reality in Psychiatry

Biomarkers and Neurobehavioral Diagnosis

Neuromodulation in Small Animal fMRI

Molecular imaging in neuroscience research with small-animal PET in rodents.

Coming full circle: In vivo Veritas, or expanding the neuroscience frontier

Molecular Tools and Approaches for Optogenetics

Elevating the field for applying neuroimaging to individual patients in psychiatry

Measuring neuroplasticity in human development: the potential to inform the type and timing of mental health interventions

In and out: Benchmarking in vitro, in vivo, ex vivo, and xenografting approaches for an integrative brain disease modeling pipeline

Neuromodulator and neuropeptide sensors and probes for precise circuit interrogation in vivo

Towards precise resting-state fMRI biomarkers in psychiatry: synthesizing developments in transdiagnostic research, dimensional models of psychopathology, and normative neurodevelopment

Advanced Neuroscience Technologies

Understanding the Pathophysiology of Mental Diseases and Early Diagnosis Thanks to Electrophysiological Tools: Some Insights and Empirical Facts

Optogenetic and chemogenetic approaches for modeling neurological disorders in vivo

Stereo-Electroencephalography–Guided Network Neuromodulation for Psychiatric Disorders: The Neurophysiology Monitoring Unit